Liver disease is a major global health problem, causing over two million deaths worldwide each year. While animal models have helped to understand liver biology, they often fail to accurately ...

Scientists have found that combining silybin with carvedilol works far better against liver fibrosis than either drug alone.

The effectiveness of non-clinical drug safety predictions is enhanced by the adoption of three-dimensional (3D) cellular models. 3D bioprinting enables the generation of complex models with spatial ...

In a bid to gain further understanding of the etiology and pathogenesis of metabolic dysfunction–associated steatohepatitis (MASH), a team of researchers has created 3D bioprinted liver models. MASH, ...

The liver has a unique structure, especially at the level of individual cells. Hepatocytes, the main liver cells, release bile into tiny channels called bile canaliculi, which drain into the bile duct ...

Liver disease takes the lives of about two million people every year around the world. The prevalence of this family of diseases, however, outpaces the evolution of therapies. So, some scientists use ...

Liver fibrosis is a progressive and potentially reversible condition that results from chronic liver damage, which can be caused by a variety of factors, including metabolic dysfunction-associated ...

Overcoming acquired treatment resistance is one of the major challenges in the fight against cancer. While combination therapies hold promise, their toxicity to healthy tissue remains a major hurdle.